1. Stanford Massie M.D. GIM Noon Conference February 12, 2008

5. JACC 2004;44:720-32

8. Log-Linear relationship of LDL and CHD risk JACC 2004;44:720-32

9. Ann Intern Med. 2006;145:520-530.

10. Diminishing returns of the hypothesized log-linear relationship Ann Intern Med. 2006;145:520-530.

15. Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women JAMA. 2007;298(7):776-785

29. NEJM 2005;352:1425-35.

31. NEJM 2005;352:1425-35.

33. NEJM 2005;352:1425-35.

34. TNT Outcomes ACP Journal Club . Sept/Oct 2005;143(2):38.

36. JACC 2006;48:438–45.

37. JACC 2006;48:438–45.

38. Risk of coronary death or MI JACC 2006;48:438–45.

39. Adverse Events in the Trials JACC 2006;48:438–45.

44. NEJM 2006;355:549-59.

46. Screening, Enrollment, and Outcomes NEJM 2006;355:549-59.

47. NEJM 2006;355:549-59. Baseline Characteristics of the Patients

49. Kaplan-Meier Curves for Stroke and TIA NEJM 2006;355:549-59.

50. Kaplan-Meier Curves for Coronary and Cardiovascular Events NEJM 2006;355:549-59.

51. SPARCL Results ACP Journal Club . Jan/Feb 2007;146(1):7.

52. SPARCL: Factors associated with increased hemorrhagic stroke risk Slide from The Heart.org, Data source: Goldstein LB et al. Neurology 2007 Factor Hazard ratio 95% CI p Atorvastatin treatment 1.68 1.09–2.59 0.02 Hemorrhagic stroke as entry event 5.65 2.82–11.30 0.001 Male sex 1.79 1.13–2.84 0.01 Increasing age (per 10-y increment) 1.42 1.16–1.74 0.001

54. Statin treatment withdrawal in ischemic stroke: A controlled randomized study Neurology 2007;69:904–910

56. Results Neurology 2007;69:904–910

60. ENHANCE Study : Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression Double blind RCT in 720 patients designed to assess changes in Carotid IMT by imaging. Study not yet published.

61. ENHANCE: LDL values at baseline and % reduction after treatment Merck/Schering-Plough Pharmaceuticals. ENHANCE trial results. January 14, 2008. Ezetimibe plus simvastatin Simvastatin alone p Baseline LDL (mg/dL) 319 318 NS Reduction after 2-y treatment (%) 58 41 <0.01

62. ENHANCE: Primary end point Merck/Schering-Plough Pharmaceuticals. ENHANCE trial results. January 14, 2008. End point Ezetimibe plus simvastatin Simvastatin alone p Change in mean carotid IMT after 2-y treatment (mm) 0.0111 0.0058 0.29

64. Recent statin trials: CHD event rates and LDL Journal of Clinical Lipidology. (2007) 1, 182–190 TNT: If results extrapolated to clinical practice, use of 80 mg atorvastatin to reduce LDL from 101 to 77 in 1000 pts with stable CAD would prevent 34 CV events over a period of 5 years. NNT to prevent one event~30.